Radiocor News

Jasper Therapeutics jumps after positive briquilimab trial

Shares up 15% premarket (Il Sole 24 Ore Radiocor) - New York, 14 Oct - Shares in Jasper Therapeutics jumped in premarket trading after the clinical-stage biotechnology company reported positive data from a trial of its novel antibody therapy briquilimab.

The company said 14 of 15 participants enrolled in the trial achieved a clinical response, 10 of 12 participants in the 120mg cohort achieved a complete response, while there were no serious adverse events.

'We are very excited to report positive data from the SPOTLIGHT study, our first readout from a clinical trial evaluating briquilimab in chronic urticaria,' said Ronald Martell, President and Chief Executive Officer of Jasper.

At 1216 GMT Jasper Therapeutics shares were up 15%.

AAA-Sje

(RADIOCOR) 14-10-24 14:31:35 (0389) 5 NNNN

 


The Exchange accepts no responsability for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.


You will be redirected in five seconds.